Clinica Cayanga Medical Resources


Clinical Updates


Clinical Updates
Alzheimer's Disease
Arthritis
Benign Prostatic Hypertrophy
Chronic Lymphocytic Leukemia
Depression
Diabetes Mellitus
Dyspepsia
Erectile Dysfunction
Fatty Liver
Gallstone
Hepatitis
Hypertension
Lung Cancer
Mesothelioma
Metabolic Syndrome
Obesity
Prostate Cancer
Stroke
Tinnitus
 
Medical Library
Breaking Medical News
Clinical Tools
Dermatology
Diabetes Corner
Evidence-Based Medicine
Free Medical Books
History Taking and Physical Examination
Free Medical Journal
Medical Journal (popular)
Medical Organizations
Palm Tools
Medical Physiology (Lecture)
Medical Resources
Medical Search
Online Clinical Calculator
 
 

 

Telmisartan (Micardis) effective on the control of Urinary Albumin Excretion (UAE) in patients with Isolated Systolic Hypertension (ISH)

 

Clinical Question: In patients with isolated systolic hypertension (ISH), which is effective on the control of urinary albumin excretion, telmisartan or hydrochlorothiazide?

Bottom Line: In patients with ISH unselected for baseline albuminuria, telmisartan 20-80 mg after 6 weeks' treatment afforded significantly greater lowering of UAE than hydrochlorothiazide 12.5 mg, irrespective of the baseline UAE, and despite comparable reductions in systolic blood pressure with both drugs.

Reference
: The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.J Hypertens. 2005 Nov;23(11):2055-2061.Vogt L, Navis G, Koster J, Manolis AJ, Reid JL, de Zeeuw D; on behalf of the Angiotensin II Receptor Antagonist Telmisartan Micardis in Isolated Systolic Hypertension (ARAMIS) Study Group.

Study Design: Randomized, Double-blind, Placebo-controlled trial

Synopsis: To examine the effect of telmisartan or hydrochlorothiazide on the control of urinary albumin excretion (UAE) in patients with isolated systolic hypertension (ISH) unselected for albuminuria in a pre-planned substudy of a large, multicentre, double-blind, placebo-controlled, randomized study. The Angiotensin II Receptor Antagonist Micardis in Isolated Systolic hypertension (ARAMIS) study compared the antihypertensive efficacy after 6 weeks of once-daily fixed doses of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo in patients (n = 1039, aged 35-84 years) with ISH (seated blood pressure 150-179/< 90 mmHg). The prospective substudy analysed UAE using spot morning samples. Urinary albumin (> 2.2-901.6 mg/l) was detected at baseline in 614 out of 918 patients who were included in the substudy analysis. In the telmisartan group (n = 354, all doses combined), a median reduction in UAE from a baseline of 14.1% [95% confidence interval (CI) 7.3, 21.8] was observed versus 1.1% (95% CI -13.5 to 16.0) and 2.7% (95% CI -0.9 to 19.9) in the hydrochlorothiazide (n = 140) and placebo (n = 120) groups, respectively. The difference between telmisartan and hydrochlorothiazide was significant (P = 0.017). Reductions in UAE with telmisartan were observed in patients with baseline normoalbuminuria, microalbuminuria or macroalbuminuria. Telmisartan and hydrochlorothiazide produced comparable reductions in systolic blood pressure in these patients.

 

 

 

   

Home | Introduction | Scheduling a Visit| Laboratory Work Reaching Us | Map to our Office | About the Doctors

 

 

 ©2005 Clinica Cayanga. All rights reserved.